Meta-Analysis of Placebo Response in Adult Antidepressant Trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Roughly 80% of the symptom improvement experienced on antidepressants in clinical trials is also observed in the placebo comparison group. Understanding the correlates of placebo improvement and response is important to designing efficient and successful trials of future antidepressants. The objective of this meta-analysis was to investigate the magnitude of placebo symptom improvement and placebo response rates in second-generation antidepressant trials of depression, anxiety, and obsessive-compulsive disorder. We searched PubMed on 10 June, 2016, with no date or language limits, to identify randomized placebo-controlled trials of second-generation antidepressants in adults with depression, anxiety, or obsessive-compulsive disorder. We used a random-effects meta-analysis to examine the magnitude of placebo symptom improvement using standardized mean difference and placebo response rate. Stratified subgroup analysis and meta-regression were utilized to examine the effect of diagnostic indication and correlates of placebo symptom improvement. The meta-analysis included 164 trials involving 19,591 participants. Magnitude of placebo improvement and placebo response rates varied significantly between diagnostic indications. The magnitude of placebo improvement was much lower in obsessive-compulsive disorder (standardized mean difference = 0.58, 95% confidence interval 0.36–0.79) than in depression (standardized mean difference = 1.22, 95% confidence interval 1.12–1.32) or anxiety (standardized mean difference = 1.01, 95% confidence interval 0.90–1.12) trials. There was a large amount of heterogeneity in placebo improvement between studies (Q = 899, df = 110, p < 0.001, I2 = 88%). A greater number of study sites and a later publication year were associated with a greater magnitude of placebo improvement and response rate. Presence of a placebo lead-in and absence of non-US sites were associated with a reduced magnitude of placebo improvement. Trial duration was positively associated with the magnitude of placebo improvement in depression trials but negatively associated with the magnitude of placebo improvement in anxiety and obsessive-compulsive disorder trials. Magnitude of placebo symptom improvement differed significantly based on diagnostic indication with improvement being significantly less in obsessive-compulsive disorder than anxiety and depression. Some trial characteristics were associated with a greater magnitude of placebo improvement in trials across disorders but others were disorder specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346
Geers, A. L., Helfer, S. G., Kosbab, K., Weiland, P. E., & Landry, S. J. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2004.08.011 · Cited by 225
Furukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164 · cited 1×
“Kirsch [8] recently reignited this debate by stating that the placebo response could account for all the clinical effectiveness demonstrated by antidepressants.”
Background
Cited by
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., Naqvi, H. A., Minhas, F. A., Carvalho, A. F., Meyer, J. H., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30138-3 · Cited by 167
Blinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Metadata
- Authors
- Li, F., Nasir, M., Olten, B., & Bloch, M. H.
- Venue
- CNS Drugs
- Published
- 2019-10
- Volume
- 33
- Issue
- 10
- Pages
- 971-980
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2977820257
- Cited by
- 42
- References
- 7
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-Analysis of Placebo Response in Adult Antidepressant Trials. https://app.cochat.ai/papers/10.1007/s40263-019-00662-y
- The paper
- Li, F., Nasir, M., Olten, B., & Bloch, M. H. (2019). Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs. https://doi.org/10.1007/s40263-019-00662-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.